8/1012 sources · 8 publishersUpdated Nov 4, 16:14 UTC
Charles River Laboratories reports Q3 2026 earnings beat and raises 2026 outlook
Charles River Laboratories posted third‑quarter 2026 revenue of $982.7 million, down about 2.2% year‑over‑year, with organic growth of 4.7%. GAAP earnings per share were $6.86 and non‑GAAP earnings per share were $3.09, both above analyst estimates. The company lifted its full‑year 2026 non‑GAAP EPS guidance to $11.35‑$11.55 per share and narrowed its expected revenue decline to 1.5%‑2.0%.
Why it matters
The company expects full‑year non‑GAAP EPS of $11.35‑$11.55 per share, up from prior expectations. It also narrowed its projected revenue decline to 1.5%‑2.0% for 2026, indicating improved outlook despite a modest revenue drop.
Key facts
- 1Q3 2026 revenue was $982.7 million, a 2.2% decline year‑over‑year. sec.gov
- 2GAAP earnings per share were $6.86 for the quarter. sec.gov
- 3Non‑GAAP earnings per share were $3.09, up 27.2% year‑over‑year. sec.gov
- 4Organic revenue grew 4.7% in the quarter. sec.gov
- 5Full‑year 2026 non‑GAAP EPS guidance was raised to $11.35‑$11.55 per share. tradingview.com
- 6Full‑year 2026 revenue decline guidance was narrowed to 1.5%‑2.0% (previously 2.5%‑3.5%). rttnews.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.